Oral Contraceptive Pills Market Report 2026

The oral contraceptive pills market size has grown rapidly in recent years. It will grow from $30.43 billion in 2025 to $34.96 billion in 2026 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increasing awareness of family planning, availability of generic pills, supportive government healthcare policies, growing prevalence of unintended pregnancies, expansion of hospital pharmacy networks.

The oral contraceptive pills market size is expected to see rapid growth in the next few years. It will grow to $61.05 billion in 2030 at a compound annual growth rate (CAGR) of 15%. The growth in the forecast period can be attributed to rise in digital healthcare platforms, technological advancements in drug delivery, increasing women’s health initiatives, expansion of online retail channels, growing demand for personalized contraceptive solutions. Major trends in the forecast period include rise in hormonal contraceptive awareness, increasing adoption of online pharmacies, growth in generic oral contraceptives, focus on low-dose and non-hormonal pills, expansion of women’s health programs.

Rising healthcare expenditure is expected to drive growth in the oral contraceptive pill market. Healthcare expenditure encompasses the total resources, including financial resources, spent on healthcare services and products within a specific timeframe. Increased healthcare spending enhances accessibility, enabling greater adoption of oral contraceptive pills through improved access to family planning services, consultations, and affordable prescriptions. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency, U.S. healthcare expenditures in 2023 rose by 7.5%, reaching $4.9 trillion, or approximately $14,570 per individual, compared to the prior year. Consequently, rising healthcare expenditures are fueling growth in the oral contraceptive pill market.

Leading companies in the oral contraceptive pill market are developing innovative products, such as progestin-only oral contraceptives, to expand their customer base, increase sales, and boost revenue. Progestin-only oral contraceptives contain a synthetic form of the hormone progestin and are an effective method of birth control. For instance, in July 2023, Perrigo Company PLC, an Ireland-based oral contraceptive manufacturer, received U.S. FDA approval for Opill, the first over-the-counter birth control pill in the United States. As a progestin-only pill, Opill provides effective pregnancy prevention while offering unprecedented accessibility, allowing women to obtain contraception without a prescription. This launch represents a milestone in women’s reproductive health and reflects Perrigo’s commitment to delivering transformative healthcare solutions.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired the manufacturing facility of Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition grants Marksans ownership of a 47,597-square-meter facility, effectively doubling its production capacity in India from 8 billion units per year. The expanded facility will be used to manufacture a variety of pharmaceutical products, including tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceutical Industries Ltd. is an Israel-based manufacturer of oral contraceptive pills.

Major companies operating in the oral contraceptive pills market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Zydus Lifesciences Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals Inc., Glenmark Pharmaceuticals, Mankind Pharma Ltd., Mayne Pharma, HLL Lifecare Limited, Famy Care Ltd., Mylan N.V., GlaxoSmithKline plc, Piramal Enterprises Ltd., Syzygy Healthcare, V Care Pharma.

North America was the largest region in the oral contraceptive pills market in 2025. The Middle East is expected to be the largest growing region in the forecast period. The regions covered in the oral contraceptive pills market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral contraceptive pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oral contraceptive pills market by increasing the cost of imported raw materials and finished drugs, leading to higher production costs and pricing pressures. The branded and combination pill segments are particularly affected, with Asia-Pacific and North American regions seeing the most significant disruption due to reliance on imports. Some manufacturers are benefiting by localizing production and diversifying supply chains, which can help reduce dependency on tariffed imports and ensure steady availability.

The oral contraceptive pills market research report is one of a series of new reports that provides oral contraceptive pills market statistics, including oral contraceptive pills industry global market size, regional shares, competitors with a oral contraceptive pills market share, detailed oral contraceptive pills market segments, market trends and opportunities, and any further data you may need to thrive in the oral contraceptive pills industry. This oral contraceptive pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral contraceptive pills are tablets containing hormones that prevent the release of eggs from the ovaries. These pills, commonly known as birth control pills, typically include both progestin and estrogen, and work to inhibit ovulation. Most oral contraceptives combine these two hormones, though some contain only progestin.

The oral contraceptive pills market is segmented by type into combination, progestin-only, and others; by category into generic and branded; and by distribution channel into hospital pharmacies, retail pharmacies, clinics, online platforms, public channels and NGOs, and other outlets.

The oral contraceptive pills market consists of sales of combined estrogen-progesterone, progesterone-only, and continuous or extended use pill. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.